Roche?s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for
- IMpassion031 data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency
- Tecentriq is the only approved cancer immunotherapy for the treatment of metastatic triple-negative breast cancer, a very aggressive and difficult-to-treat form of breast cancer
Attachment